Company
Argent BioPharma Ltd
ASX:RGT
Argent BioPharma Ltd is a European-based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant-inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions. The company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high-quality plant-inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia. Argent BioPharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.
157 stories · page 4 of 8
MGC Pharma continues focus on sales growth with reopening of upgraded factory
The planned shutdown of its Slovenian plant and seasonal trends were responsible for the fall in revenue to US$765k in the September quarter
MGC Pharmaceuticals delivers positive Long-COVID clinical study results
“That the product could help to explain changes in the symptoms of Long-COVID patients is an extremely promising development for the company, with significant potential commercial developments we hope to explore further through future studi
MGC Pharma achieves a series of major operational and quality milestones
"It is important the business is well positioned to service demand, both in terms of our production capacity, and the progress of our products through the clinical pipeline," said the company's managing director Roby Zomer
MGC Pharmaceuticals hits key European and US milestones
MGC has also fast-tracked production to deliver 50,000 units of ArtemiC™ Rescue to AMC Holdings in a single shipment.
MGC Pharmaceuticals appoints Hannam & Partners as UK capital markets advisor; transitions board
The company has tapped Hannam & Partners as financial and corporate advisors in an effort to maximise enterprise value. At the same time, the company has appointed a new chief operating officer and transitioned chair Brett Mitchell into a n
MGC Pharmaceuticals Ltd appoints new COO and UK advisor
Yifat Steuer has over 20 years of experience as an executive, working across a range of pharmaceutical companies including Johnson & Johnson and GlaxoSmithKline
MGC Pharma shares jump 8% after it reveals encouraging early data from dosing study
None of the 16 patients administered CimetrA demonstrated significant complications related to the illness
MGC Pharmaceuticals delivers encouraging results from CimetrA dose-finding study against COVID-related infections
Preclinical and clinical results to date have demonstrated CimetrA™'s mechanism of action as an anti-inflammatory and immunomodulatory agent which is effective in the prevention of an infection of the different variants of SARS-CoV-2.
MGC Pharma sees sales jump 57%
The company specialises in developing plant-based and cannabis-derived treatments for ailments as diverse as inflammatory diseases, Covid and cancer
MGC Pharmaceuticals makes final project payment for phytomedicine manufacturing hub
MGC Pharma is targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.
MGC Pharmaceuticals secures additional ~US$1 million order for anti-inflammatory product
3,500 units of ArtemiC Rescue already delivered to AMC, resulting in the new purchase order to be delivered into the US over the next 3 months.